219 related articles for article (PubMed ID: 32369821)
1. Mutational Profiling of Driver Tumor Suppressor and Oncogenic Genes in Brazilian Malignant Pleural Mesotheliomas.
Campanella NC; Silva EC; Dix G; de Lima Vazquez F; Escremim de Paula F; Berardinelli GN; Balancin M; Chammas R; Mendoza Lopez RV; Silveira HCS; Capelozzi VL; Reis RM
Pathobiology; 2020; 87(3):208-216. PubMed ID: 32369821
[TBL] [Abstract][Full Text] [Related]
2. Comparative genetic analysis of a rare synchronous collision tumor composed of malignant pleural mesothelioma and primary pulmonary adenocarcinoma.
Naka T; Hatanaka Y; Marukawa K; Okada H; Hatanaka KC; Sakakibara-Konishi J; Oizumi S; Hida Y; Kaga K; Mitsuhashi T; Matsuno Y
Diagn Pathol; 2016 Apr; 11():38. PubMed ID: 27091358
[TBL] [Abstract][Full Text] [Related]
3. Genetic alterations of malignant pleural mesothelioma: association with tumor heterogeneity and overall survival.
Quetel L; Meiller C; Assié JB; Blum Y; Imbeaud S; Montagne F; Tranchant R; de Wolf J; Caruso S; Copin MC; Hofman V; Gibault L; Badoual C; Pintilie E; Hofman P; Monnet I; Scherpereel A; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Mol Oncol; 2020 Jun; 14(6):1207-1223. PubMed ID: 32083805
[TBL] [Abstract][Full Text] [Related]
4. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.
Lo Iacono M; Monica V; Righi L; Grosso F; Libener R; Vatrano S; Bironzo P; Novello S; Musmeci L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2015 Mar; 10(3):492-9. PubMed ID: 25514803
[TBL] [Abstract][Full Text] [Related]
5. Identification of actionable mutations in malignant pleural mesothelioma.
Shukuya T; Serizawa M; Watanabe M; Akamatsu H; Abe M; Imai H; Tokito T; Ono A; Taira T; Kenmotsu H; Naito T; Murakami H; Takahashi T; Endo M; Ohde Y; Nakajima T; Yamamoto N; Koh Y
Lung Cancer; 2014 Oct; 86(1):35-40. PubMed ID: 25174276
[TBL] [Abstract][Full Text] [Related]
6. Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition.
de Reyniès A; Jaurand MC; Renier A; Couchy G; Hysi I; Elarouci N; Galateau-Sallé F; Copin MC; Hofman P; Cazes A; Andujar P; Imbeaud S; Petel F; Pairon JC; Le Pimpec-Barthes F; Zucman-Rossi J; Jean D
Clin Cancer Res; 2014 Mar; 20(5):1323-34. PubMed ID: 24443521
[TBL] [Abstract][Full Text] [Related]
7. Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup.
Pirker C; Bilecz A; Grusch M; Mohr T; Heidenreich B; Laszlo V; Stockhammer P; Lötsch-Gojo D; Gojo J; Gabler L; Spiegl-Kreinecker S; Dome B; Steindl A; Klikovits T; Hoda MA; Jakopovic M; Samarzija M; Mohorcic K; Kern I; Kiesel B; Brcic L; Oberndorfer F; Müllauer L; Klepetko W; Schmidt WM; Kumar R; Hegedus B; Berger W
Clin Cancer Res; 2020 Jul; 26(14):3819-3830. PubMed ID: 32317288
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis of the EGFR gene and downstream signalling pathway in histologic samples of malignant pleural mesothelioma.
Mezzapelle R; Miglio U; Rena O; Paganotti A; Allegrini S; Antona J; Molinari F; Frattini M; Monga G; Alabiso O; Boldorini R
Br J Cancer; 2013 Apr; 108(8):1743-9. PubMed ID: 23558893
[TBL] [Abstract][Full Text] [Related]
10. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing.
Mäki-Nevala S; Sarhadi VK; Knuuttila A; Scheinin I; Ellonen P; Lagström S; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuutila S
Lung; 2016 Feb; 194(1):125-35. PubMed ID: 26463840
[TBL] [Abstract][Full Text] [Related]
11. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer.
Kuang S; Fung AS; Perdrizet KA; Chen K; Li JJN; Le LW; Cabanero M; Karsaneh OAA; Tsao MS; Morganstein J; Ranich L; Smith AC; Wei C; Cheung C; Shepherd FA; Liu G; Bradbury P; Pal P; Schwock J; Sacher AG; Law JH; Stockley TL; Leighl NB
Curr Oncol; 2022 Jun; 29(7):4428-4437. PubMed ID: 35877212
[TBL] [Abstract][Full Text] [Related]
12. Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma.
Tallet A; Nault JC; Renier A; Hysi I; Galateau-Sallé F; Cazes A; Copin MC; Hofman P; Andujar P; Le Pimpec-Barthes F; Zucman-Rossi J; Jaurand MC; Jean D
Oncogene; 2014 Jul; 33(28):3748-52. PubMed ID: 23975423
[TBL] [Abstract][Full Text] [Related]
13. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
[TBL] [Abstract][Full Text] [Related]
14. [Expression and clinical significance of SETD2 in maligant pleural mesothelioma].
Yu M; Yu M; Zhu LJ; Yuan XY; Zhang X
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2021 Feb; 39(2):91-98. PubMed ID: 33691361
[No Abstract] [Full Text] [Related]
15. Complex Genomic Rearrangement Patterns in Malignant Pleural Mesothelioma due to Environmental Asbestos Exposure.
Tuncel T; Ak G; Güneş HV; Metintaş M
J Environ Pathol Toxicol Oncol; 2024; 43(2):13-27. PubMed ID: 38505910
[TBL] [Abstract][Full Text] [Related]
16. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
[TBL] [Abstract][Full Text] [Related]
17. Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
De Rienzo A; Archer MA; Yeap BY; Dao N; Sciaranghella D; Sideris AC; Zheng Y; Holman AG; Wang YE; Dal Cin PS; Fletcher JA; Rubio R; Croft L; Quackenbush J; Sugarbaker PE; Munir KJ; Battilana JR; Gustafson CE; Chirieac LR; Ching SM; Wong J; Tay LC; Rudd S; Hercus R; Sugarbaker DJ; Richards WG; Bueno R
Cancer Res; 2016 Jan; 76(2):319-28. PubMed ID: 26554828
[TBL] [Abstract][Full Text] [Related]
18. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
19. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.
Kang HC; Kim HK; Lee S; Mendez P; Kim JW; Woodard G; Yoon JH; Jen KY; Fang LT; Jones K; Jablons DM; Kim IJ
Oncotarget; 2016 Feb; 7(7):8321-31. PubMed ID: 26824986
[TBL] [Abstract][Full Text] [Related]
20. Hot spot mutations in Finnish non-small cell lung cancers.
Mäki-Nevala S; Sarhadi VK; Rönty M; Kettunen E; Husgafvel-Pursiainen K; Wolff H; Knuuttila A; Knuutila S
Lung Cancer; 2016 Sep; 99():102-10. PubMed ID: 27565922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
